4,5-二溴噻吩-2-甲酸 | 6324-10-3

• 物质功能分类: 医药中间体 - 噻吩类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 4,5-二溴噻吩-2-甲酸
• 英文名称: 4,5-Dibromo-thiophene-2-carboxylic acid
• 英文别名: 4,5-dibromo-2-thiophenecarboxylic acid；4,5-Dibromothiophene-2-carboxylic acid
• CAS: 6324-10-3
• 化学式: C₅H₂Br₂O₂S
• mdl: MFCD00039682
• 分子量: 285.944
• InChiKey: USFXRYVNRUMABJ-UHFFFAOYSA-N

物化性质

• 熔点：
  227-228°C
• 沸点：
  367.1±42.0 °C(Predicted)
• 密度：
  2.309±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  常温常压下稳定，是一种具有恶臭气味的固体。

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  65.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 安全说明：
  S22,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  请将药品存放在避光、阴凉干燥处，并密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4,5-Dibromothiophene-2-carboxylic acid
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 4,5-Dibromothiophene-2-carboxylic acid
CAS number: 6324-10-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
This product should be handled only by, or under the close supervision of, those properly qualified
Handling:
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C5H2Br2O2S
Molecular weight: 285.9

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4,5-二溴噻吩-2-甲酸 在 氯化亚砜 作用下， 以100%的产率得到4,5-二溴-2-噻吩羰酰氯
  参考文献：
  名称：

  间隔基扩展的Bis-Ene-Yne化合物：范围，局限性和属性

  摘要：

  噻吩对双烯炔化合物的裂解反应已得到系统地研究。这些多功能积木的便捷可及性为功能性有机材料中的新颖应用铺平了道路。

  DOI：

  10.1002/ejoc.201800446
• 作为产物：
  描述：

  2-噻吩甲酸 在 溴 作用下， 以 sodium hydroxide 为溶剂， 生成 4,5-二溴噻吩-2-甲酸
  参考文献：
  名称：

  Phosphorylamides, their preparation and use

  摘要：

  一种由通式（I）表示的磷酰胺衍生物：##STR1## 其中R代表可能被取代的氨基团或其盐，对幽门螺杆菌，特别是幽门螺杆菌，具有强效的抗菌活性，并可用于单独或与抗酸剂或酸分泌抑制剂联合预防或治疗由幽门螺杆菌引起的消化系统疾病。

  公开号：

  US05840917A1

文献信息

• Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US06291514B1

  公开（公告）日：2001-09-18

  The present invention is directed to compounds of Formula I: wherein X is O, S or NR7 and R1-R7, Y and Z are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, plasmin and urokinase. Certain of the compounds exhibit direct, selective inhibition of urokinase, or are intermediates useful for forming compounds having such activity.

  本发明涉及以下式的化合物： 其中X为O、S或NR7，R1-R7、Y和Z如规范中所述，并且其水合物、溶剂合物或药用可接受的盐也被描述。还描述了制备上述式化合物的方法。本发明的新化合物是蛋白酶的有效抑制剂，特别是胰蛋白酶样丝氨酸蛋白酶，如凝血酶、胰蛋白酶、纤溶酶和尿激酶。其中某些化合物表现出对尿激酶的直接、选择性抑制，或者是用于形成具有这种活性的化合物的中间体。
• Compounds and compositons for treating C1s-mediated diseases and conditions
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20020037915A1

  公开（公告）日：2002-03-28

  Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I 1 or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R 1 , R 2 , R 3 , R 4 , X, Y and Z are defined in the specification.

  揭示了一种治疗急性或慢性疾病症状的方法，该疾病是由补体级联的经典途径介导的，包括向需要此类治疗的哺乳动物施用化合物I的治疗有效量或其溶剂化合物、水合物或药用可接受盐；其中规范中定义了R1、R2、R3、R4、X、Y和Z。
• From Synthetic Simplified Marine Metabolite Analogues to New Selective Allosteric Inhibitor of Aurora B Kinase
  作者：Charlotte Juillet、Ludmila Ermolenko、Dina Boyarskaya、Blandine Baratte、Béatrice Josselin、Hristo Nedev、Stéphane Bach、Bogdan I. Iorga、Jérôme Bignon、Sandrine Ruchaud、Ali Al-Mourabit

  DOI：10.1021/acs.jmedchem.0c02064

  日期：2021.1.28

  (37). Here we present the synthesis of new inhibitors of Aurora B kinase, which is an important target for cancer therapy through mitosis regulation. The biologically oriented synthesis yielded several nanomolar inhibitors. The optimized compound CJ2-150 (37) showed a non-ATP competitive allosteric mode of action in a mixed-type inhibition for Aurora B kinase. Molecular docking identified a probable binding

  通过合成属于海绵的海洋吡咯-2-氨基咪唑代谢产物的苯并ceptors和oroidin的简化片段，可以实现对Aurora B的显着抑制。激酶抑制作用的评估使得能够发现可合成获得的刚性炔属结构类似物EL-228（1），其结构可以优化为有效的CJ2-150（37）。在这里，我们介绍了新的Aurora B激酶抑制剂的合成，该抑制剂是通过有丝分裂调节进行癌症治疗的重要靶标。生物定向合成产生了几种纳摩尔抑制剂。优化的化合物CJ2-150（37）在Aurora B激酶的混合型抑制中显示了非ATP竞争性变构作用模式。分子对接在变构位点“ F”中确定了可能的结合模式，并强调了与蛋白质的关键相互作用。我们描述了新型支架的抑制力和特异性的提高以及作用机理的表征。
• Escaping from Flatland: Antimalarial Activity of sp³-Rich Bridged Pyrrolidine Derivatives
  作者：Brian Cox、James Duffy、Victor Zdorichenko、Corentin Bellanger、Jessica Hurcum、Benoît Laleu、Kevin I. Booker-Milburn、Luke D. Elliott、Michael Robertson-Ralph、Christopher J. Swain、Stephen J. Bishop、Irene Hallyburton、Mark Anderson

  DOI：10.1021/acsmedchemlett.0c00486

  日期：2020.12.10

  We utilized synthetic photochemistry to generate novel sp3-rich scaffolds and report the design, synthesis, and biological testing of a diverse series of amides based on the 1-(amino-methyl)-2-benzyl-2-aza-bicyclo[2.1.1]hexane scaffold. Preliminary antimalarial screening of the library provided promising compounds with activity in the 1–5 μM range with an enhanced hit rate. Further evaluation (solubility

  我们利用合成光化学生成了新型富含sp 3 的支架，并报告了基于 1-（氨基-甲基）-2-苄基-2-氮杂-双环 [2.1 .1]己烷支架。该文库的初步抗疟筛选提供了有希望的化合物，其活性范围为 1–5 μM，并具有更高的命中率。所选化合物 ( 9 ) 的进一步评估（溶解度、药物代谢和药代动力学 (DMPK) 和毒性）表明，该系列代表了进一步优化的绝佳机会，该框架为添加独特的矢量定位的额外功能提供了多种机会。
• Heterobicyclic pyrazole derivatives as kinase inhibitors
  申请人：Tonani Roberto

  公开号：US20060160874A1

  公开（公告）日：2006-07-20

  Bicyclo-pyrazoles of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

  公开了如规范中定义的化学式（I）的双环吡唑及其药用盐，其制备方法以及包含它们的药物组合物；本发明的化合物在治疗中可能有用，用于治疗与异常蛋白激酶活性相关的疾病，如癌症。